EXACT SCIENCES CORP (EXAS) Cost of Revenue (2010 - 2025)

Exact Sciences (EXAS) has reported Cost of Revenue for 14 consecutive years, with $262.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cost of Revenue rose 18.89% year-over-year to $262.6 million; the TTM figure through Dec 2025 stood at $984.2 million (up 17.15% YoY), while the FY2025 annual figure was $984.2 million, up 17.15% from the prior year.
• Cost of Revenue retreated to $262.6 million in Q4 2025 per EXAS's latest filing, from $266.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $266.8 million in Q3 2025 and bottomed at $110.0 million in Q1 2021.
• Historically, Cost of Revenue has averaged $184.1 million across 5 years, with a median of $190.3 million in 2023.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 96.64% — and 2023, when it declined 17.58%.
• Exact Sciences' Cost of Revenue stood at $119.1 million in 2021, then soared by 96.64% to $234.1 million in 2022, then slipped by 17.58% to $193.0 million in 2023, then grew by 14.44% to $220.8 million in 2024, then advanced by 18.89% to $262.6 million in 2025.
• Business Quant data shows EXAS's Cost of Revenue at $262.6 million in Q4 2025, $266.8 million in Q3 2025, and $248.6 million in Q2 2025.